Protara Announces Pricing of $75 Million Public Offering

Core Viewpoint - Protara Therapeutics, Inc. has announced a public offering of 13,043,479 shares of common stock priced at $5.75 per share, aiming to raise approximately $75 million for clinical development and other corporate purposes [1]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,956,521 shares at the public offering price [1]. - The offering is expected to close on December 8, 2025, pending customary closing conditions [1]. - Protara intends to use the net proceeds for the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1]. Group 2: Underwriters and Management - J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering [2]. - LifeSci Capital is serving as the lead manager, while H.C. Wainwright & Co. is acting as a manager of the offering [2]. Group 3: Regulatory Information - The shares will be issued under an effective shelf registration statement on Form S-3, declared effective on November 14, 2023, by the U.S. Securities and Exchange Commission [3]. - A final prospectus supplement will be filed with the SEC and will be available on their website [3].